Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Exelixis, Inc. Grows Revenue, Eyes Treating More Patients

TheMotleyFool 
0 0 04.08.17
Exelixis, Inc. Grows Revenue, Eyes Treating More Patients
 
Exelixis, Inc. Grows Revenue, Eyes Treating More Patients

Sales of Exelixis' (NASDAQ: EXEL) kidney cancer drug Cabometyx continued to grow at a torrid pace in the second quarter, allowing the company to post another profitable quarter.

Metric

Q2 2017

Continue reading


Source: Fool.com

Bristol-Myers Squibb Stock

€43.56
-2.540%
A loss of -2.540% shows a downward development for Bristol-Myers Squibb.
We see a rather positive sentiment for Bristol-Myers Squibb with 7 Buy predictions and 2 Sell predictions.
With a target price of 70 € there is a hugely positive potential of 60.7% for Bristol-Myers Squibb compared to the current price of 43.56 €.
Show more
Like: 0
BMY
Share

Comments

Not a member yet? Sign up for free!